Deals channel feed – Endpoints News

Deals channel feed

Its sale to Allergan was called off at the last minute. One year later, a biotech co-founded by Henri Termeer finds a new buyer

5 years ago

Pfizer infuses $200M into CStone, scoring a second PD-L1 and outlining a sprawling China pact

5 years ago

Armed with a PhI cancer drug from Bayer, an Acerta founder breaks cover and writes himself a $60M blank check deal

5 years ago

Play-by-play of Gilead's $21B Immunomedics buyout details a frenzied push — and mints a new biotech billionaire

5 years ago

Two wild weeks for Grail end in $8B Illumina buyout

5 years ago

Roche vaults to the front of the NLRP3 clinical race, paying $448M upfront to bag Inflazome

5 years ago

Roche looks to genetic modifiers for new drug targets, teaming up with Dutch biotech in $375M deal

5 years ago

#ESMO20: Trodelvy data show that Gilead's $21B buyout may have been worth the big premium

5 years ago

Stronger together? Boehringer and Mirati team to put first KRAS-KRAS combo in the clinic

5 years ago

Moderna picks up a $75M cash windfall as longtime collaborator Vertex signs up for a gene editing assault on cystic fibrosis

5 years ago

Forget the IPO, Illumina is nearing a buyout of $1.9B liquid biopsy startup Grail — report

5 years ago

The central figure in Nestlé's $2.6B Aimmune buyout? Covid-19

5 years ago

Akcea’s board managed to get Ionis to boost its buyout bid a bit, but never got close to a 2019 acquisition offer

5 years ago

Attempting to bounce back after mid-stage flop, Novus pivots to immunology with CD40L-focused acquisition of Anelixis

5 years ago

Here's a look at everything Merck's BD group has done in the past 12 years, illustrating why the Seattle Genetics deal stands out

5 years ago

Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa

5 years ago

Gilead CEO Dan O'Day's $21B M&A deal to buy Immunomedics gets some harsh reviews

5 years ago

After Novartis left, Boehringer bets up to $500M on the field of prescription smartphone apps

5 years ago

Brent Saunders pivots from Allergan sale to a $460M SPAC, making him an overnight player in one of the hottest money-raising gambits in biotech

5 years ago

Recursion nabs $239M and an up to $1B partnership with Bayer as AI race heats up

5 years ago

Paying down more debt, Takeda offloads prescription drug portfolio for $562 million

5 years ago

Dabbling in CD47, Pfizer infuses $25M into a biotech player touting positive monotherapy data

5 years ago

Ahead of merger with Pfizer's generic unit, Mylan makes $757M+ purchase for European thrombosis portfolio

5 years ago

Grifols makes a $146M bet on a Stanford play in a controversial anti-aging field

5 years ago

First page Previous page 85 86 878889 90 91 Next page Last page